OTC · Biotechnology

Bavarian Nordic A/S (BVNRY) Stock

$9.15 -0.65% OTC: BVNRY Healthcare

Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypox (known as IMVAMUNE, IMVANEX, and JYNNEOS), as well as human rabies protection (Rabipur/RabAvert), a tick-borne encephalitis vaccine (Encepur), and an Ebola vaccine (MVABEA).

Valuation

MetricValue
Price$9.15
Market Cap$2.12B
P/E Ratio12.33
P/B Ratio1.09
P/S Ratio2.30
EPS (TTM)$0.74
52-Week High$13.00
52-Week Low$8.67
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE9.25%
ROA8.32%
ROCE11.39%
Gross Margin47.40%
Operating Margin25.36%
Net Margin19.83%
Debt/Equity0.01
Current Ratio6.47

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.9B$3.2B$7.1B$5.7B$5.9B
Operating Profit$-263.0M$-4.0M$1.5B$940.0M$885.0M
Net Profit$-465.0M$-347.0M$1.5B$988.0M$1.3B
EPS$-2.46$-1.64$6.41$4.20$5.66
Op Margin-13.9%-0.1%21.2%16.4%14.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$12.1B$12.4B$14.4B$14.4B$15.0B
Total Liabilities$4.7B$5.2B$4.0B$3.0B$2.1B
Cash$592.0M$575.0M$1.5B$1.6B$1.7B
Borrowings$1.1B$1.8B$145.0M$128.0M$131.0M

Latest News

Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil GlobeNewswire · Jul 13, 2026 Bavarian Nordic – Completion of Share Buy-Back Program GlobeNewswire · Jul 13, 2026 Bavarian Nordic – Transactions in Connection with Share Buy-Back Program GlobeNewswire · Jul 6, 2026 Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine GlobeNewswire · Jun 29, 2026 Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine GlobeNewswire · Jun 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-358.0M$220.0M$1.1B$1.9B$2.6B
Investing Cash Flow$-3.9B$-2.3B$-1.9B$-3.6B$-2.6B
Financing Cash Flow$-86.0M$-31.0M$-86.0M$-69.0M$-184.0M
Net Cash Flow$306.0M$-16.0M$902.0M$146.0M$281.0M
Free Cash Flow$-1.4B$-1.2B$142.0M$262.0M$2.4B

Valuation & Return Ratios

MetricValue
PEG Ratio-0.96
EV / EBITDA5.81
FCF Yield10.10%
Quick Ratio3.58
Interest Coverage128.19
Return 1Y-4.50%
Return 3Y—
Return 5Y—

Ownership

Insiders Held0.00%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
Rhumbline Advisers6,1692026-03-31
Curio Wealth, LLC 12026-03-31
Gamma Investing LLC192026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Bavarian Nordic A/S

Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypox (known as IMVAMUNE, IMVANEX, and JYNNEOS), as well as human rabies protection (Rabipur/RabAvert), a tick-borne encephalitis vaccine (Encepur), and an Ebola vaccine (MVABEA). The company also boasts a robust pipeline of investigational therapies. Notably, MVA-BN (freeze-dried) has concluded Phase III trials for smallpox, and MVA-BN RSV is currently in Phase III clinical development for respiratory syncytial virus (RSV). Additionally, ABNCoV2, a candidate for SARS-CoV-2, successfully completed its Phase II clinical trial, and TAEK-VAC is advancing through Phase I/II studies for select advanced HER2 and brachyury-expressing cancers. Bavarian Nordic maintains strategic alliances, including a licensing and collaboration agreement with AdaptVac, alongside further licensing arrangements with the National Cancer Institute and the Public Health Service. Its commercial operations and presence span numerous countries, such as the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, and Japan, reflecting a broad international footprint. Established in 1992, Bavarian Nordic A/S is headquartered in Hellerup, Denmark.

Bavarian Nordic A/S is headquartered in DK.

Bavarian Nordic A/S (BVNRY) stock trades at $9.15 with a market capitalization of $2.12B. The stock is valued at a price-to-earnings (P/E) ratio of 12.33, price-to-book of 1.09, price-to-sales of 2.30. Over the past 52 weeks the stock has ranged between $8.67 and $13.00, and currently trades 29.6% below its 52-week high.

On profitability, Bavarian Nordic A/S generates a return on equity (ROE) of 9.25%, return on capital employed of 11.39%, an operating margin of 25.36%, a net profit margin of 19.83%.

Official website: www.bavarian-nordic.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides